FOR IMMEDIATE RELEASE
NEW YORK, NY., May 5, 2018 – Luminus Diagnostics, a full-service specialty lab based in Tifton, Georgia, was in attendance at the annual American Psychiatric Association (APA) in New York City to introduce Amplis™ Medication Guidance Reporting, a decision support tool for clinicians based on advanced genetic technologies. The newly-offered test can provide physicians and patients with insight into proper medication guidance and dosage recommendations.
The multiple day meeting, hosted at Jacob Javitz Center in Manhattan from May 5 – May 9, is offering over 500 training sessions to Psychiatry and Healthcare Professionals with a focus on “Building Well-Being Through Innovation,” the theme of this year’s event. With innovation in mind, Luminus Diagnostics developed testing methods for Amplis™ Medication Guidance, opening the doors to potential future scientific findings, developments and research.
The company is excited to bring Amplis™ to the APA Annual Meeting and unveil it to the psychiatric health community, physicians and patients. As attendees begin making their way into the exhibition hall, Luminus Diagnostic employees are preparing to illuminate the industry to an important and invaluable genetic test.
Recent Research suggests that depressed patients who received antidepressants medication for the first time, responded well only 30% – 50% of the time. These odds could improve significantly as the test becomes more widely utilized by licensed psychiatric professionals for their patients.
Luminus Diagnostics is a full-service, specialty laboratory and integrated technology platform designed to illuminate patient insight, streamline ordering and optimize practice performance. Providing advanced technology integration to streamline practice diagnostic ordering with timely, accurate testing and exceptional customer service.